Dudediligence.

Dianthus Therapeutics, Inc

DNTHNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$2.2MSep ’24$1.3MDec ’24$1.2MMar ’25$193,000Jun ’25$396,000Sep ’25$284,000Dec ’25
Net income, by quarter
−$25.2MSep ’24−$28.4MDec ’24−$29.5MMar ’25−$31.6MJun ’25−$36.8MSep ’25−$64.4MDec ’25−$40.8MMar ’26−$50.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on file$2.8M$6.2M$2.0M
Operating income−$74.7M−$29.7M−$48.2M−$101.9M−$177.9M
Net income−$71.1M−$28.5M−$43.6M−$85.0M−$162.3M
Operating cash flow−$59.5M−$29.1M−$36.9M−$78.2M−$129.1M
Free cash flow−$60.8M−$29.4M−$37.0M−$78.3M−$129.3M
Cash$131.7M$15.4M$132.3M$22.8M$51.1M
Shares outstanding58.8M875.3K14.8M31.1M43.2M